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Cancer of the appendix is a rare neoplasm; only a few
thousand cases per year are reported in the US. The
average busy general surgeon will encounter a case
approximately once per decade. When peritoneal
dissemination occurs, as it often does, it may lead to
mucinous ascites, also known as pseudomyxoma
peritonei. Such peritoneal dissemination results in a
slowly progressive process, which ultimately leads to
death as a result of bowel obstruction. Most appen-
diceal cancers are low-grade neoplasms that are typ-
ically relatively indolent. This low-grade/indolent
behavior has led some to suggest a nonaggressive
approach to therapy. Despite this, a number of cen-
ters have chosen to pursue aggressive cytoreductive
surgery and intraperitoneal chemotherapy.
In the August issue of the Annals of Surgical
Oncology, one of the leading proponents of aggressive
cytoreductive surgery with intraperitoneal chemo-
therapy for disseminated peritoneal surface disease
from appendiceal tumors presents his experience.1
This is a landmark report of the outcomes of 402
patients treated with cytoreductive surgery and
intraperitoneal chemotherapy, representing more
than a decades focused work in this area. This rep-
resents an enormous volume of work in patients with
stage IV disease. The 10-year survival is a remarkable
85% in patients who are able to undergo complete
cytoreduction with intraperitoneal chemotherapy for
disseminated (predominantly) low-grade appendiceal
carcinoma. However, it is critical to bear in mind
what this means for appendiceal cancer patients, and
even more importantly, what it does not.
Patients with peritoneal carcinomatosis from ap-
pendiceal cancers who are taken to the operating
room for cytoreductive surgery must expect a for-
midable procedure.2–4 After aggressive efforts to re-
move all apparent disease, a complete (CCR0-1 or
R0-1) resection is achieved in approximately half of
the cases.2,3 Those that can be completely cytore-
duced represent the most favorable subset. Patients
who cannot be adequately cytoreduced (debulked)
fare much more poorly.2,4,5 Furthermore, this cohort
consisted predominantly of tumors of low histologi-
cal grade, which also has signiﬁcantly better out-
comes than high-grade appendiceal tumors.6 Thus,
this cohort represents the best of the best of cases
treated as part of an extensive experience of over 1000
patients with peritoneal surface disease at the
Washington Hospital Center.
Other issues should be considered in the evaluation
of this article. The long-term follow-up in this study is
excellent. However, predicting 10-year survival with
mean follow-up of only 66 months may suggest
somewhat better results than will actually be found
with longer follow-up. Additionally, although
patients received intraperitoneal hyperthermic
chemotherapy (HIPEC or IPHC), additional early
postoperative intraperitoneal chemotherapy (EPIC)
was utilized selectively by criteria that are not crisply
deﬁned.
Despite these weaknesses, there are a number of
important pieces of information to be mined from
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this article. First and foremost is that complete
resection and intraperitoneal chemotherapy can yield
excellent outcomes with prolonged disease-free sur-
vival. Clearly, the majority of the beneﬁt arises from
cytoreductive surgery. However, this begs the ques-
tion of the value of the intraperitoneal chemotherapy;
whether in the form of intraoperative intraperitoneal
hyperthermic chemotherapy (HIPEC) or early post-
operative intraperitoneal chemotherapy (EPIC). To
date, a deﬁnitive randomized trial comparing cyto-
reductive surgery with or without IPHC (HIPEC)
and/or EPIC has not been completed. While the
disease-free survival in this study is superior to re-
ports of cytoreductive surgery alone, this supports,
but does not prove, its value.7
The 28% of cases that recurred after aggressive
cytoreductive surgery in IP chemotherapy were typi-
cally treated with a repeat cytoreductive procedure
and additional intraperitoneal chemotherapy. Repeat
(second or even third) cytoreductive surgery are
challenging procedures associated with similar out-
comes to those of the initial procedure only if com-
plete cytoreduction can be achieved. The use of
cisplatinum and doxorubicin in recurrences in this
setting is a curious choice as neither of these agents is
particularly active against colorectal carcinoma. De-
spite this, the results support the use of repeat pro-
cedures when the disease does recur, if there is no
extra-abdominal disease and complete cytoreduction
is feasible.8 It is also noteworthy that the mean sur-
vival of those not chosen for repeat procedures is 30
months. This length of survival for unresected
recurrent disease should be borne in mind when
evaluating patients with recurrences.
The outcomes after cytoreductive surgery with IP
chemotherapy are closely related to the completeness
of cytoreduction. The high rates of complete cytore-
duction with lower volumes of peritoneal disease [as
measured by the peritoneal carcinomatosis index
(PCI)] suggest that early intervention is appropriate.
Patients presenting with voluminous mucinous ascites
(pseudomyxoma peritonei) are much less likely to be
able to undergo complete cytoreduction. Thus, when
low-volume peritoneal disease is encountered, it does
not seem prudent to wait for massive, symptomatic
disease to develop before undertaking cytoreductive
procedures. It should also be remembered that the
mucinous ascites is a byproduct of the tumor, not the
primary target of the cytoreduction per se; thus re-
moval of the tumor producing the mucin is the pri-
mary goal of cytoreduction, not evacuation of
accumulated mucinous ascites.
The use of systemic therapy is not discussed in this
article. However, the 10-year overall survival achieved
with cytoreductive surgery and intraperitoneal che-
motherapy strongly refute a role of systemic chemo-
therapy in this setting. The observation that most of
the peritoneal failures are potential candidates for
further cytoreductive surgery with intraperitoneal
chemotherapy also argues against a role for external
beam radiation therapy. However, systemic therapy
may be of value in patients with recurrent disease no
longer amenable to cytoreduction.
Much has been learned and many centers have
initiated programs for cytoreductive surgery and
intraperitoneal therapy in the 13 years since the
database in this article was initiated. This therapy
requires aggressive surgery associated with a signiﬁ-
cant learning curve.9 Concentrating these cases at
regional centers with experience of cytoreductive
surgery, peritoniectomy procedures and intraperito-
neal therapy should beneﬁt patients. The rarity of
appendiceal carcinoma makes randomized trials ex-
tremely difﬁcult to complete. Nevertheless, those of
us who regularly treat this disease need to martial our
resources to initiate such trials.
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